​

Royalty Pharma (RPRX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

RPRX Stock Forecast

Royalty Pharma (RPRX) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $49.40, with a high of $61.00 and a low of $42.00. This represents a 7.70% increase from the last price of $45.87.

$25 $33 $41 $49 $57 $65 High: $61 Avg: $49.4 Low: $42 Last Closed Price: $45.87

RPRX Stock Rating

Royalty Pharma stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (90.91%), 1 Hold (9.09%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 1 10 Strong Sell Sell Hold Buy Strong Buy

RPRX Price Target Upside V Benchmarks

TypeNameUpside
StockRoyalty Pharma7.70%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts136
Avg Price Target$50.00$53.33$50.17
Last Closing Price$45.87$45.87$45.87
Upside/Downside9.00%16.26%9.37%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26361--10
Feb, 2636---9
Jan, 26351--9
Dec, 25351--9
Nov, 25351--9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 27, 2026Seaport Global$50.00$46.218.20%9.00%
Feb 12, 2026Terence FlynnMorgan Stanley$61.00$44.7136.43%32.98%
Jan 30, 2026Ashwani VermaUBS$49.00$40.8619.92%6.82%
Dec 11, 2025Leerink Partners$45.00$38.2217.74%-1.90%
Sep 30, 2025Goldman Sachs$42.00$35.2519.15%-8.44%
Jul 10, 2025Terence FlynnMorgan Stanley$54.00$36.1449.42%17.72%
Sep 04, 2024Chris ShibutaniGoldman Sachs$51.00$29.1674.90%11.18%
Jul 11, 2024Terence FlynnMorgan Stanley$51.00$25.7398.21%11.18%
Jun 07, 2024Chris ShibutaniGoldman Sachs$50.00$27.0984.57%9.00%
Jun 03, 2024Ashwani VermaUBS$28.00$27.352.38%-38.96%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 27, 2026Seaport GlobalNeutralupgrade
Feb 12, 2026Goldman SachsBuyBuyhold
Feb 12, 2026Morgan StanleyOverweightOverweighthold
Jan 30, 2026UBSNeutralBuyupgrade
Jan 27, 2026CitigroupBuyBuyhold
Dec 11, 2025Cowen & Co.BuyBuyhold
Oct 10, 2025Morgan StanleyOverweightOverweighthold
Sep 30, 2025Goldman SachsBuyBuyinitialise
Jul 10, 2025Morgan StanleyOverweightOverweighthold
Mar 28, 2025CitigroupBuyBuyhold

Financial Forecast

EPS Forecast

$0 $1 $2 $3 $4 $5 $6 $7 $8 $9 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.49$0.10$2.54$1.92$1.79---
Avg Forecast$2.86$3.64$4.24$4.05$4.40$4.98$7.16$8.00
High Forecast$3.14$3.83$4.25$4.08$5.02$6.14$7.42$8.29
Low Forecast$2.59$3.30$4.23$4.01$4.13$4.24$6.56$7.33
Surprise %-47.90%-97.25%-40.09%-52.59%-59.32%---

Revenue Forecast

$2B $2B $3B $4B $4B $5B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.29B$2.24B$2.35B$2.26B$2.38B---
Avg Forecast$2.16B$2.79B$2.99B$2.70B$2.98B$3.30B$3.94B$4.39B
High Forecast$2.31B$2.91B$3.01B$2.71B$3.00B$3.41B$4.05B$4.52B
Low Forecast$2.00B$2.59B$2.97B$2.52B$2.95B$3.19B$3.69B$4.11B
Surprise %6.21%-19.85%-21.14%-16.07%-20.12%---

Net Income Forecast

$0 $1B $2B $3B $4B $5B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$619.73M$42.83M$1.13B$858.98M$770.95M---
Avg Forecast$645.49M$475.79M$1.13B$2.44B$2.76B$3.13B$4.22B$4.82B
High Forecast$774.59M$570.94M$1.36B$2.46B$3.03B$3.70B$4.47B$5.00B
Low Forecast$516.39M$380.63M$907.87M$2.42B$2.49B$2.55B$3.96B$4.42B
Surprise %-3.99%-91.00%--64.77%-72.05%---

RPRX Forecast FAQ

Is Royalty Pharma stock a buy?

Royalty Pharma stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Royalty Pharma is a favorable investment for most analysts.

What is Royalty Pharma's price target?

Royalty Pharma's price target, set by 11 Wall Street analysts, averages $49.4 over the next 12 months. The price target range spans from $42 at the low end to $61 at the high end, suggesting a potential 7.70% change from the previous closing price of $45.87.

How does Royalty Pharma stock forecast compare to its benchmarks?

Royalty Pharma's stock forecast shows a 7.70% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Royalty Pharma over the past three months?

  • March 2026: 30.00% Strong Buy, 60.00% Buy, 10.00% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 33.33% Strong Buy, 55.56% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.

What is Royalty Pharma’s EPS forecast?

Royalty Pharma's average annual EPS forecast for its fiscal year ending in December 2026 is $4.98, marking a 178.21% increase from the reported $1.79 in 2025. Estimates for the following years are $7.16 in 2027, and $8 in 2028.

What is Royalty Pharma’s revenue forecast?

Royalty Pharma's average annual revenue forecast for its fiscal year ending in December 2026 is $3.3B, reflecting a 38.87% increase from the reported $2.38B in 2025. The forecast for 2027 is $3.94B, and $4.39B for 2028.

What is Royalty Pharma’s net income forecast?

Royalty Pharma's net income forecast for the fiscal year ending in December 2026 stands at $3.13B, representing an 305.52% increase from the reported $770.95M in 2025. Projections indicate $4.22B in 2027, and $4.82B in 2028.